Advances in local ablation therapy for liver cancer with portal hypertension

Wen LUO; Jun TIE

doi:10.3969/j.issn.1001-5256.2021.03.005

Volume 37 Issue 3

Mar. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(3): 515-521

PDF( 1871 KB)

Advances in local ablation therapy for liver cancer with portal hypertension

DOI: 10.3969/j.issn.1001-5256.2021.03.005

Wen LUO¹,
Jun TIE^{2
,
,}

1.
Department of Ultrasound, Xijing Hospital, Air Force Medical University, Xi'an 710032, China
2.
Department of Digestive Interventional Radiology, Xijing Hospital of Digestive Diseases, Air Force Medical University, Xi'an 710032, China

Received Date: 2020-12-08
Accepted Date: 2020-12-16
Published Date: 2021-03-20

Abstract

Abstract

With the comprehensive application of a variety of treatment methods, the survival time of patients with primary liver cancer is gradually increasing. For patients with early-stage liver cancer and portal hypertension, local ablation therapy can achieve long-term survival and play a positive role in stabilizing portal venous pressure, preserving liver function, and reducing complications. In addition, it can be combined with other techniques such as transarterial chemoembolization, transjugular intrahepatic portosystemic shunt, splenectomy, and pericardial devascularization to further improve treatment outcome. Several measures can be taken in the perioperative period to improve the management efficiency of patients after ablation, such as objective evaluation of portal venous pressure, prevention of esophagogastric variceal bleeding, correction of hypersplenism, prevention of postoperative liver failure, and multidisciplinary team management.
- Hepatocellular Carcinoma,
- Hypertension, Portal,
- Catheter Ablation

FullText(HTML)

References(45)

References

[1]	Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.05.009 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.05.009
[2]	European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019
[3]	OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370. DOI: 10.1007/s12072-017-9799-9
[4]	HERNANDEZ-GEA V, TURON F, BERZIGOTTI A, et al. Management of small hepatocellular carcinoma in cirrhosis: Focus on portal hypertension[J]. World J Gastroenterol, 2013, 19(8): 1193-1199. DOI: 10.3748/wjg.v19.i8.1193
[5]	BRUIX J, REIG M, SHERMAN M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma[J]. Gastroenterology, 2016, 150(4): 835-853. DOI: 10.1053/j.gastro.2015.12.041
[6]	RUBINSTEIN MM, KAUBISCH A, KINKHABWALA M, et al. Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantation[J]. J Gastrointest Oncol, 2017, 8(6): 1051-1055. DOI: 10.21037/jgo.2017.08.11
[7]	KAO WY, CHAO Y, CHANG CC, et al. Prognosis of early-stage hepatocellular carcinoma: The clinical implications of substages of Barcelona Clinic Liver Cancer System based on a cohort of 1265 patients[J]. Medicine (Baltimore), 2015, 94(43): e1929. DOI: 10.1097/MD.0000000000001929
[8]	XIAO H, ZHANG B, MEI B, et al. Hepatic resection for hepatocellular carcinoma in patients with portal hypertension: A long-term benefit compared with transarterial chemoembolization and thermal ablation[J]. Medicine (Baltimore), 2015, 94(7): e495. DOI: 10.1097/MD.0000000000000495
[9]	MORISE Z. Laparoscopic liver resection for the patients with hepatocellular carcinoma and chronic liver disease[J]. Transl Gastroenterol Hepatol, 2018, 3: 41. DOI: 10.21037/tgh.2018.07.01
[10]	YOUNG S, GOLZARIAN J. Locoregional therapies in the treatment of 3- to 5-cm hepatocellular carcinoma: Critical review of the literature[J]. AJR Am J Roentgenol, 2020, 215(1): 223-234. DOI: 10.2214/AJR.19.22098
[11]	QIU J, ZHENG Y, SHEN J, et al. Resection versus ablation in hepatitis B virus-related hepatocellular carcinoma patients with portal hypertension: A propensity score matching study[J]. Surgery, 2015, 158(5): 1235-1243. DOI: 10.1016/j.surg.2015.04.002
[12]	HARADA N, SHIRABE K, MAEDA T, et al. Comparison of the outcomes of patients with hepatocellular carcinoma and portal hypertension after liver resection versus radiofrequency ablation[J]. World J Surg, 2016, 40(7): 1709-1719. DOI: 10.1007/s00268-016-3465-6
[13]	KARABULUT K, AUCEJO F, AKYILDIZ HY, et al. Resection and radiofrequency ablation in the treatment of hepatocellular carcinoma: A single-center experience[J]. Surg Endosc, 2012, 26(4): 990-997. DOI: 10.1007/s00464-011-1983-8
[14]	ZOU H, WU LQ. A propensity score matching analysis of hepatectomy and radiofrequency ablation for patients with solitary hepatocellular carcinoma less than or equal to 5 cm and portal hypertension[J]. Chin J Dig Surg, 2018, 17(10): 1018-1023. (in Chinese) 邹浩, 吴力群. 肝切除术与射频消融术治疗单发肿瘤直径≤5 cm肝细胞癌合并门静脉高压症患者的倾向评分匹配疗效分析[J]. 中华消化外科杂志, 2018, 17(10): 1018-1023.
[15]	WANG HL, DAI CL, ZHAO Y, et al. Comparison of liver resection vs. microwave ablation for patients with hepatocellular carcinoma and portal hypertension in early stage[J]. J Abdominal Surg, 2017, 30(2): 103-108. (in Chinese) https://www.cnki.com.cn/Article/CJFDTOTAL-FBWK201702008.htm 王鹤霖, 戴朝六, 赵阳, 等. 伴有门静脉高压症的早期肝癌病人肝切除与微波消融的疗效比较[J]. 腹部外科, 2017, 30(2): 103-108. https://www.cnki.com.cn/Article/CJFDTOTAL-FBWK201702008.htm
[16]	JIANG L, YAN L, WEN T, et al. Comparison of outcomes of hepatic resection and radiofrequency ablation for hepatocellular carcinoma patients with multifocal tumors meeting the Barcelona-Clinic Liver Cancer Stage A Classification[J]. J Am Coll Surg, 2015, 221(5): 951-961. DOI: 10.1016/j.jamcollsurg.2015.08.009
[17]	LEE S, JEONG WK, RHIM H. Repeated percutaneous radiofrequency ablation for hepatocellular carcinoma in patients with cirrhosis: Assessment of safety based on liver function and portal hypertension parameters[J]. J Vasc Interv Radiol, 2014, 25(10): 1573-1579. DOI: 10.1016/j.jvir.2014.06.015
[18]	KIM PN, CHOI D, RHIM H, et al. Planning ultrasound for percutaneous radiofrequency ablation to treat (< 3 cm) hepatocellular carcinomas detected on computed tomography or magnetic resonance imaging: A multicenter prospective study to assess factors affecting ultrasound visibility[J]. J Vasc Interv Radiol, 2012, 23(5): 627-634. DOI: 10.1016/j.jvir.2011.12.026
[19]	SANTAMBROGIO R, BARABINO M, BRUNO S, et al. Long-term outcome of laparoscopic ablation therapies for unresectable hepatocellular carcinoma: A single European center experience of 426 patients[J]. Surg Endosc, 2016, 30(5): 2103-2113. DOI: 10.1007/s00464-015-4468-3
[20]	CILLO U, VITALE A, DUPUIS D, et al. Laparoscopic ablation of hepatocellular carcinoma in cirrhotic patients unsuitable for liver resection or percutaneous treatment: A cohort study[J]. PLoS One, 2013, 8(2): e57249. DOI: 10.1371/journal.pone.0057249
[21]	DÍAZ-GONZÁLEZ Á, VILANA R, BIANCHI L, et al. Thermal ablation for intrahepatic cholangiocarcinoma in cirrhosis: Safety and efficacy in non-surgical patients[J]. J Vasc Interv Radiol, 2020, 31(5): 710-719. DOI: 10.1016/j.jvir.2019.06.014
[22]	JIA Z, ZHANG K, JIANG L, et al. Simultaneous radiofrequency ablation combined with laparoscopic splenectomy: A safe and effective way for patients with hepatocellular carcinoma complicated with cirrhosis and hypersplenism[J]. Minim Invasive Ther Allied Technol, 2020, 29(3): 177-184. DOI: 10.1080/13645706.2019.1609990
[23]	PEI Y, CHAI S, ZHANG Y, et al. Benefits of splenectomy and curative treatments for patients with hepatocellular carcinoma and portal hypertension: A retrospective study[J]. J Gastrointest Surg, 2019, 23(11): 2151-2162. DOI: 10.1007/s11605-018-3981-9
[24]	CHENG J, WU WD, HU ZM, et al. Simultaneous microwave ablation therapy combined with laparoscopic splenectomy plus pericardial devascularization for the treatment of small hepatocellular carcinoma with portal hypertension[J]. Chin J Hepatobiliary Surg, 2019, 25(8): 622-624. (in Chinese) http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgdwk201908014 成剑, 吴伟顶, 胡智明, 等. 微波消融联合腹腔镜脾切除加贲门周围血管离断术治疗小肝癌合并门静脉高压症[J]. 中华肝胆外科杂志, 2019, 25(8): 622-624. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhgdwk201908014
[25]	ZHANG K, JIANG L, JIA Z, et al. Radiofrequency ablation plus devascularization is the preferred treatment of hepatocellular carcinoma with esophageal varices[J]. Dig Dis Sci, 2015, 60(5): 1490-1501. DOI: 10.1007/s10620-014-3455-1
[26]	HU K, LEI P, YAO Z, et al. Laparoscopic RFA with splenectomy for hepatocellular carcinoma[J]. World J Surg Oncol, 2016, 14(1): 196. DOI: 10.1186/s12957-016-0954-x
[27]	ZHENG L, LI HL, GUO CY, et al. Comparison of the efficacy and prognostic factors of transarterial chemoembolization plus microwave ablation versus transarterial chemoembolization alone in patients with a large solitary or multinodular hepatocellular carcinomas[J]. Korean J Radiol, 2018, 19(2): 237-246. DOI: 10.3348/kjr.2018.19.2.237
[28]	SAVIANO A, IEZZI R, GIULIANTE F, et al. Liver resection versus radiofrequency ablation plus transcatheter arterial chemoembolization in cirrhotic patients with solitary large hepatocellular carcinoma[J]. J Vasc Interv Radiol, 2017, 28(11): 1512-1519. DOI: 10.1016/j.jvir.2017.06.016
[29]	BOSCH J, ABRALDES JG, BERZIGOTTI A, et al. The clinical use of HVPG measurements in chronic liver disease[J]. Nat Rev Gastroenterol Hepatol, 2009, 6(10): 573-582. DOI: 10.1038/nrgastro.2009.149
[30]	YANG W, YAN K, GOLDBERG SN, et al. Ten-year survival of hepatocellular carcinoma patients undergoing radiofrequency ablation as a first-line treatment[J]. World J Gastroenterol, 2016, 22(10): 2993-3005. DOI: 10.3748/wjg.v22.i10.2993
[31]	WANG K, LIU G, LI J, et al. Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: A prospective cohort study[J]. Eur J Surg Oncol, 2015, 41(2): 236-242. DOI: 10.1016/j.ejso.2014.11.002
[32]	WU WC, CHIOU YY, HUNG HH, et al. Prognostic significance of computed tomography scan-derived splenic volume in hepatocellular carcinoma treated with radiofrequency ablation[J]. J Clin Gastroenterol, 2012, 46(9): 789-795. DOI: 10.1097/MCG.0b013e31825ceeb5
[33]	ARIO K, MIZUTA T, EGUCHI Y, et al. Presence of esophageal varices is a risk factor for non-hemorrhagic death of hepatocellular carcinoma patients treated with radiofrequency ablation[J]. Hepatogastroenterology, 2010, 57(99-100): 501-506. http://new.med.wanfangdata.com.cn/Paper/Detail?id=PeriodicalPaper_JJ0216294688
[34]	KIM R, JEONG WK, KANG TW, et al. Intrahepatic distant recurrence after radiofrequency ablation of hepatocellular carcinoma: relationship with portal hypertension[J]. Acta Radiol, 2019, 60(12): 1609-1618. DOI: 10.1177/0284185119842830
[35]	FANG KC, SU CW, CHIOU YY, et al. The impact of clinically significant portal hypertension on the prognosis of patients with hepatocellular carcinoma after radiofrequency ablation: A propensity score matching analysis[J]. Eur Radiol, 2017, 27(6): 2600-2609. DOI: 10.1007/s00330-016-4604-z
[36]	LLOVET JM, BRU C, BRUIX J. Prognosis of hepatocellular carcinoma: The BCLC staging classification[J]. Semin Liver Dis, 1999, 19: 329-338. DOI: 10.1055/s-2007-1007122
[37]	BERZIGOTTI A. Non-invasive evaluation of portal hypertension using ultrasound elastography[J]. J Hepatol, 2017, 67(2): 399-411. DOI: 10.1016/j.jhep.2017.02.003
[38]	BERZIGOTTI A, SEIJO S, ARENA U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis[J]. Gastroenterology, 2013, 144(1): 102-111. e1. DOI: 10.1053/j.gastro.2012.10.001
[39]	EL SHERBINY W, ABDELRAHMAN A, DIASTY M, et al. Changes in Doppler parameters of portal pressure after interventional management of hepatocellular carcinoma[J]. Abdominal radiology, 2016, 41(8): 1532-1538. DOI: 10.1007/s00261-016-0704-0
[40]	KIM H, CHOI D, LEE JH, et al. High-risk esophageal varices in patients treated with locoregional therapy for hepatocellular carcinoma: Assessment with liver computed tomography[J]. World J Gastroenterol, 2012, 18(35): 4905-4911. DOI: 10.3748/wjg.v18.i35.4905
[41]	QIU B, ZHAO MF, YUE ZD, et al. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension[J]. World J Gastroenterol, 2015, 21(43): 12439-12447. DOI: 10.3748/wjg.v21.i43.12439
[42]	PARK JK, AL-TARIQ QZ, ZAW TM, et al. Radiofrequency ablation for the treatment of hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts[J]. Cardiovasc Intervent Radiol, 2015, 38(5): 1211-1217. DOI: 10.1007/s00270-015-1050-2
[43]	SONOMURA T, KAWAI N, KISHI K, et al. N-butyl cyanoacrylate embolization with blood flow control of an arterioportal shunt that developed after radiofrequency ablation of hepatocellular carcinoma[J]. Korean J Radiol, 2014, 15(2): 250-253. DOI: 10.3348/kjr.2014.15.2.250
[44]	WU TT, LI HC, ZHENG F, et al. Percutaneous endovascular radiofrequency ablation for malignant portal obstruction: An initial clinical experience[J]. Cardiovasc Intervent Radiol, 2016, 39(7): 994-1000. DOI: 10.1007/s00270-016-1317-2
[45]	GABA RC, KALLWITZ ER, PARVINIAN A, et al. Imaging surveillance and multidisciplinary review improves curative therapy access and survival in HCC patients[J]. Ann Hepatol, 2013, 12(5): 766-773. DOI: 10.1016/S1665-2681(19)31318-3

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (675) PDF downloads(78)

Advances in local ablation therapy for liver cancer with portal hypertension

DOI: 10.3969/j.issn.1001-5256.2021.03.005

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Advances in local ablation therapy for liver cancer with portal hypertension

DOI: 10.3969/j.issn.1001-5256.2021.03.005

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content